Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9Y3Z3

UPID:
SAMH1_HUMAN

ALTERNATIVE NAMES:
Dendritic cell-derived IFNG-induced protein; Monocyte protein 5; SAM domain and HD domain-containing protein 1

ALTERNATIVE UPACC:
Q9Y3Z3; B4E2A5; E1P5V2; Q5JXG8; Q8N491; Q9H004; Q9H005; Q9H3U9

BACKGROUND:
The protein SAMHD1, with alternative names such as Monocyte protein 5, is pivotal in antiviral defense and DNA repair. It restricts HIV-1 by depleting dNTPs necessary for viral replication and facilitates DNA end resection at stalled replication forks, highlighting its dual role in cellular protection and genome stability.

THERAPEUTIC SIGNIFICANCE:
Given SAMHD1's role in diseases like Aicardi-Goutieres syndrome 5 and Chilblain lupus 2, deciphering its mechanisms offers a promising avenue for developing targeted therapies, underscoring the therapeutic potential of this protein in combating related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.